Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

October 01, 1996; Volume 24,Issue 10
  • You have access
    The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations.
    R S Obach
    Drug Metabolism and Disposition October 1996, 24 (10) 1047-1049;
  • You have access
    Stereoselective irreversible binding of ketoprofen glucuronides to albumin. Characterization of the site and the mechanism.
    N Presle, F Lapicque, S Fournel-Gigleux, J Magdalou and P Netter
    Drug Metabolism and Disposition October 1996, 24 (10) 1050-1057;
  • You have access
    Systemic clearance and demethylation of caffeine in sheep and cattle.
    T J Danielson and L R Golsteyn
    Drug Metabolism and Disposition October 1996, 24 (10) 1058-1061;
  • You have access
    Comparative toxicokinetics of methanol in pregnant and nonpregnant rodents.
    K W Ward and G M Pollack
    Drug Metabolism and Disposition October 1996, 24 (10) 1062-1070;
  • You have access
    Excretion and metabolism of tipredane, a novel glucocorticoid, in the rat, mouse, monkey, and human.
    A E Cooper, A J Gray, J Collington, H Seddon, I Beattie and C J Logan
    Drug Metabolism and Disposition October 1996, 24 (10) 1071-1080;
  • You have access
    Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
    W G Karam, J A Goldstein, J M Lasker and B I Ghanayem
    Drug Metabolism and Disposition October 1996, 24 (10) 1081-1087;
  • You have access
    Reversal of stereoselectivity in the hepatic availability of verapamil in isolated perfused rat livers. Role of protein binding.
    R Mehvar and J Reynolds
    Drug Metabolism and Disposition October 1996, 24 (10) 1088-1094;
  • You have access
    Regulation of rat hepatic sulfotransferase gene expression by glucocorticoid hormones.
    M Runge-Morris, K Rose and T A Kocarek
    Drug Metabolism and Disposition October 1996, 24 (10) 1095-1101;
  • You have access
    Disposition of a novel recombinant antithrombotic agent, RG 12986, in cynomolgus monkeys.
    D S Wells, R Hensel, C Loullis, P Brophy, M E Mullin, E Murray and G Ricca
    Drug Metabolism and Disposition October 1996, 24 (10) 1102-1106;
  • You have access
    Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat.
    R Oelkers, M Ionac, K Erb, K Brune and G Geisslinger
    Drug Metabolism and Disposition October 1996, 24 (10) 1107-1110;
  • You have access
    Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    J H Lin, M Chiba, S K Balani, I W Chen, G Y Kwei, K J Vastag and J A Nishime
    Drug Metabolism and Disposition October 1996, 24 (10) 1111-1120;
  • You have access
    The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism.
    N Holtbecker, M F Fromm, H K Kroemer, E E Ohnhaus and H Heidemann
    Drug Metabolism and Disposition October 1996, 24 (10) 1121-1123;
  • You have access
    Isolation and identification of metabolites of leukotriene A4 hydrolase inhibitor SC-57461 in rats.
    J H Yuan, J Birkmeier, D C Yang, J D Hribar, N Liu, R Bible, E Hajdu, M Rock and G Schoenhard
    Drug Metabolism and Disposition October 1996, 24 (10) 1124-1133;
  • You have access
    Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human.
    R A McLellan, R K Drobitch, M Monshouwer and K W Renton
    Drug Metabolism and Disposition October 1996, 24 (10) 1134-1138;
  • You have access
    Metabolism of an atypical antipsychotic agent, 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2, 5,5-trimethyl-4-thiazolidinone (HP236).
    A E Mutlib, J Jurcak and N Hrib
    Drug Metabolism and Disposition October 1996, 24 (10) 1139-1150;
  • You have access
    Characterization of glucuronidated phase II metabolites of the immunosuppressant cyclosporine in urine of transplant patients using time-of-flight secondary-ion mass spectrometry.
    K Meyer, M Fobker, U Christians, M Erren, K F Sewing, G Assmann and A Benninghoven
    Drug Metabolism and Disposition October 1996, 24 (10) 1151-1154;
  • You have access
    Role of altered metabolism in dideoxynucleoside pharmacokinetics. Studies of 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats.
    D Singhal, M E Morgan and B D Anderson
    Drug Metabolism and Disposition October 1996, 24 (10) 1155-1161;
  • You have access
    Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs.
    N A Farid, K M Schreiner, N L Coleman, R B Van Lier and S A Wrighton
    Drug Metabolism and Disposition October 1996, 24 (10) 1162-1165;
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition
Vol. 24, Issue 10
1 Oct 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics